Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pirtobrutinib in Elderly Patients With CLL
NCT07685717Phase 2Recruiting
- Start
- Jul 2026
- Primary completion
- Dec 2027
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pirtobrutinib in chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). Primary endpoints: Rate of treatment discontinuation and Overall response rate. Started Jul 2026; status: recruiting.
02
Drugs
pirtobrutinib
03
Conditions
chronic lymphocytic leukemia (CLL)small lymphocytic lymphoma (SLL)
Beyond the preview
Go deeper on NCT07685717.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07685717.